Product Description
INI-2004 is an allergen agnostic immunotherapy that binds and activates Toll-like receptor 4. When delivered intranasally, INI-2004 dramatically reduced measures of AR in pre-clinical animal models.
Mechanisms of Action: TLR4 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Inimmune
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Rhinitis, Allergic
Phase 1: Rhinitis, Allergic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06038279 |
INI-2004-101 | P1 |
Unknown status |
Rhinitis, Allergic |
2024-11-01 |
22% |
2025-10-01 |